Altamira: 'mRNA Delivery Platform Versatile and Efficient Alternative to Lipid Nanoparticles'

 

• Altamira's peptide-based SemaPhore™ nanoparticle technology confers great stability to mRNA, is non-immunogenic and non-toxic, enabling delivery to extrahepatic targets and efficient endosomal release

• Continued momentum in mRNA vaccines and therapeutics with over 840 programs under development, according to fresh data from Beacon RNA database by Hanson Wade

• Limitations of hitherto dominant lipid nanoparticle (LNP) technologies call for alternate mRNA delivery solutions

https://finance.yahoo.com/news/altamira-therapeutics-positions-patented-semaphore-135800990.html